Summit Therapeutics Sub, Inc.
Director, Forecasting & Customer Insights
Summit Therapeutics Sub, Inc., Princeton, New Jersey, us, 08543
Overview
The Director of Forecasting and Customer Insights will play a pivotal role in driving the success of our commercial strategies and ensuring operational excellence within our pharmaceutical company. This role will be responsible for various aspects of commercial, including forecasting modeling, both US and Global, CMC vial modeling, customer insights to inform forecast, (Demand Studies) and other market research responsibilities directed towards the launch of ivonescimab. Role and Responsibilities
Develop forecasting models in oncology by tumor, for both US and Global, eventually moving from an annualized strategic model to a month over month launch model. Translate the commercial forecast model into a CMC model, providing insights to CMC for demand of vials and 3PL inventories. Conduct Market Research to gain customer insights to inform the forecast, including Patient Journey, Driver and Barriers and ATUs that will lead to Qual and Quant demand studies to more accurately predict the forecast. Conduct market analysis and assess the competitive landscape to identify opportunities & risks and collaborate with key stakeholders, (CMC, Marketing, Finance, Ops, and Sr Management) on revising forecast and assumptions. Translate commercial questions into customer insight/market research plans to address critical questions. Work with Operations to evaluate “go to market” models and optimizing field territories. All other duties as assigned. Experience, Education and Specialized Knowledge and Skills
Bachelor's degree in business administration, marketing, or related field; MBA or advanced degree preferred. A minimum of 10+ years of experience in market research and forecasting expertise within the pharmaceutical or biotechnology industry, with a track record of success in strategic planning and execution. Experience in oncology solid tumor forecasting is required, with experience in forecasting IO products preferred. Strong analytical skills and ability to translate data into actionable insights. Experience working with Veeva/Veeva Compass, IQVIA, Medidata, Salesforce or other analytical databases and Microsoft Suite. Excellent leadership and communication skills, with the ability to effectively collaborate across functions and influence stakeholders at all levels, especially CMC, Finance, and Commercial (sales and marketing). In-depth knowledge of pharmaceutical sales processes, market dynamics, and regulatory environment. Ability to thrive in a fast-paced, dynamic environment and adapt to changing priorities. Compensation
The pay range for this role is $200,000-$240,000 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation. Location: Princeton, NJ onsite 4x a week Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF. Summit has begun its clinical development of ivonescimab in NSCLC, with three active Phase III trials: HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib). HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression. Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting .
#J-18808-Ljbffr
The Director of Forecasting and Customer Insights will play a pivotal role in driving the success of our commercial strategies and ensuring operational excellence within our pharmaceutical company. This role will be responsible for various aspects of commercial, including forecasting modeling, both US and Global, CMC vial modeling, customer insights to inform forecast, (Demand Studies) and other market research responsibilities directed towards the launch of ivonescimab. Role and Responsibilities
Develop forecasting models in oncology by tumor, for both US and Global, eventually moving from an annualized strategic model to a month over month launch model. Translate the commercial forecast model into a CMC model, providing insights to CMC for demand of vials and 3PL inventories. Conduct Market Research to gain customer insights to inform the forecast, including Patient Journey, Driver and Barriers and ATUs that will lead to Qual and Quant demand studies to more accurately predict the forecast. Conduct market analysis and assess the competitive landscape to identify opportunities & risks and collaborate with key stakeholders, (CMC, Marketing, Finance, Ops, and Sr Management) on revising forecast and assumptions. Translate commercial questions into customer insight/market research plans to address critical questions. Work with Operations to evaluate “go to market” models and optimizing field territories. All other duties as assigned. Experience, Education and Specialized Knowledge and Skills
Bachelor's degree in business administration, marketing, or related field; MBA or advanced degree preferred. A minimum of 10+ years of experience in market research and forecasting expertise within the pharmaceutical or biotechnology industry, with a track record of success in strategic planning and execution. Experience in oncology solid tumor forecasting is required, with experience in forecasting IO products preferred. Strong analytical skills and ability to translate data into actionable insights. Experience working with Veeva/Veeva Compass, IQVIA, Medidata, Salesforce or other analytical databases and Microsoft Suite. Excellent leadership and communication skills, with the ability to effectively collaborate across functions and influence stakeholders at all levels, especially CMC, Finance, and Commercial (sales and marketing). In-depth knowledge of pharmaceutical sales processes, market dynamics, and regulatory environment. Ability to thrive in a fast-paced, dynamic environment and adapt to changing priorities. Compensation
The pay range for this role is $200,000-$240,000 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation. Location: Princeton, NJ onsite 4x a week Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF. Summit has begun its clinical development of ivonescimab in NSCLC, with three active Phase III trials: HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib). HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression. Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting .
#J-18808-Ljbffr